Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

BTG Reports Positive Results From Second US Pivotal Phase III Trial Of Varisolve

BTG Plc (BGC.L) announced the successful outcome of VANISH-1, the second and final US pivotal Phase III trial of Varisolve (polidocanol endovenous microfoam (PEM)) as a potential treatment for patients with saphenofemoral junction incompetence and symptomatic and/or visible varicose veins. All end points were met with all active PEM concentrations with a high degree of statistical significance, the company said.

Patients treated with PEM showed a statistically significant improvement in symptoms, the primary endpoint, versus patients who received placebo. The co-secondary endpoints of improvement in appearance in PEM-treated patients compared with patients who received placebo, as measured by both a patient-reported outcome and by a blinded independent panel review of photographs, were also met.

In addition, the three tertiary endpoints, response to treatment as determined by duplex ultrasound, change in the Venous Clinical Severity Score and Quality of Life as measured by the modified VEINES-QOL/Sym questionnaire, were all statistically significantly better for patients treated with PEM compared to patients who received placebo.

Click here to receive FREE breaking news email alerts for BTG plc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Toyota Motor Corp. (TM, TYT.L) Thursday announced 1.1 percent decline in worldwide production for October, as there was a sharp decline in production of passenger cars in Japan. Production outside Japan improved 2.3 percent. In a separate announcement, the Japanese automaker said it will recall more... Computer and printer maker Hewlett-Packard Co. said Tuesday after the markets closed that its fourth quarter profit fell 6% from last year, as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. This organic and natural products company has experienced strong compounded annual growth over the last four fiscal years with its net sales growing 25% and adjusted income from continuing operations over 30%.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.